Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ultrasound study reveals stomach risks for patients on popular diabetes drugs

NCT ID NCT06003985

Knowledge-focused Sponsor: Hospital for Special Surgery, New York Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study used a simple bedside ultrasound to check if patients taking GLP-1 agonist drugs (like Ozempic or Mounjaro) have more food or liquid in their stomach before surgery compared to those not on these drugs. Researchers enrolled 354 adults and looked for signs of delayed stomach emptying. The goal is to better understand if these medications increase the risk of complications during anesthesia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GLP-1 agonists (semaglutide, dulaglutide, tirzepatide)
What this could lead to
If successful, this could help doctors know if GLP-1 drugs increase the risk of having food in the stomach during surgery, which could improve safety guidelines.
What could go wrong
This is a small, completed observational study, not a treatment trial. It only measures stomach contents with ultrasound, so it cannot prove cause and effect or change practice on its own.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

354 people

The number who actually took part.

Started

Aug 2023

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will be comprised of patients scheduled for surgery at HSS who meet the following inclusion criteria and none of the exclusion criteria.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * GLP 1 patient group: any patient on GLP1 agonists that are dosed once per week (semaglutide, dulaglutide, tirzepatide), for all indications. * Control group (No GLP 1 patients): any patient not on GLP1 agonists that are dosed once per week, for all indications. Exclusion Criteria: * patient refusal to participate * patients with gastric bypass or any other gastric surgery * large hiatal hernia * patients with large ascites * patients on peritoneal dialysis * emergency surgery * pre-existing diagnosis of gastroparesis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric ultrasound are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric ultrasound Glucagon-like peptide 1 Point-of-care ultrasound

Contacts and locations

Locations

  • Albany Medical Center

    Albany, New York, 12208, United States

  • George Washington University Hospital

    Washington D.C., District of Columbia, 20037, United States

  • Hospital for Special Surgery

    New York, New York, 10021, United States

  • Mayo Clinic

    Jacksonville, Florida, 32224, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • University Health Network

    Toronto, Ontario, M5G 2C4, Canada

  • University of Virginia

    Charlottesville, Virginia, 22903, United States

  • Weill Cornell Medicine

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.